Targeting STAT3 in cancer: How successful are we?

Expert Opinion on Investigational Drugs

Volumn 18, Issue 1, 2009, Pages 45-56

  Yue, Peibin ^a   Turkson, James ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antitumor therapeutics; Cancer; Molecular targeted therapy; Small molecule inhibitors; STAT3

Indexed keywords

CATECHOL DERIVATIVE; CPA 1; CPA 7; CUCURBITACIN; DECOY OLIGONUCLEOTIDE; FURANONE DERIVATIVE; G QUARTET OLIGONUCLEOTIDE; GALIELLALACTONE; HEXAPEPTIDE; IS 3 295; ISS 610; JSI 124; OLIGONUCLEOTIDE; OXAZOLE DERIVATIVE; PEPTIDE; PEPTIDE APTAMER; PEPTIDOMIMETIC AGENT; PHOSPHOPEPTIDE; PHOSPHOTYROSINE LEUCYLPROLYLGLUTAMYLTHREONYLVALINE; PLATINUM DERIVATIVE; PLATINUM TETRACHLORIDE; PROLYLPHOSPHOTYROSINE LEUCYLLYSYLTHREONYLLYSINE; PROTEIN INHIBITOR; PROTEIN SH2; S 3I 201; S 3I M 2001; STA 21; STAT3 PROTEIN; STATTIC; T 40214; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DRUG DNA BINDING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; NEOPLASM; NONHUMAN; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 64849111865     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780802565791     Document Type: Review

References (80)

1. Darnell JE Jr. STATs and gene regulation. Science 1997;277(5332):1630- 1635 (Pubitemid 27446219)
2. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004;8(5):409-422 (Pubitemid 39359648)
3. Schroder M, Kroeger KM, Volk HD, et al. Preassociation of nonactivated STAT3 molecules demonstrated in living cells using bioluminescence resonance energy transfer: a new model of STAT activation? J Leukoc Biol 2004;75(5):792-797
4. Sehgal PB. Paradigm shifts in the cell biology of STAT signaling. Semin Cell Dev Biol 2008;19:329-340
5. Liu L, McBride KM, Reich NC. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci USA 2005;102(23):8150-8155 (Pubitemid 40800058)
6. Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005;2(6):315-324 (Pubitemid 40903176)
7. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11(12):1314-1321 (Pubitemid 41752912)
8. Kortylewski M, Yu H. Stat3 as a potential target for cancer immunotherapy. J Immunother 2007;30(2):131-139 (Pubitemid 46667794)
9. Yu H, Jove R. The STATs of cancer: new molecular targets come of age. Nat Rev Cancer 2004;4(2):97-105 •• A critical review of the molecular mechanisms of Stat3-mediated tumorigenesis. (Pubitemid 38198738)
10. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005;11 (6):595-596 (Pubitemid 40868294)
11. Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007;104(18):7391-7396 •• One of the examples of nonpeptidic inhibitors of Stat3 by disruption of Stat3 dimerization. (Pubitemid 47185916)
12. Siddiquee KA, Gunning PT, Glenn M, et al. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol 2007;2(12):787-798 (Pubitemid 351166054)
13. Jing N, Zhu Q, Yuan P, et al. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol Cancer Ther 2006;5(2):279-286
14. Weerasinghe P, Garcia GE, Zhu Q, et al. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol 2007;31(1):129-136
15. Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001;276(48):45443-45455 •• First proof-of-concept for inhibition of Stat3 by peptide derivatives. (Pubitemid 37406612)
16. McMurray JS. A new small-molecule Stat3 inhibitor. Chem Biol 2006;13(11):1123-1124 (Pubitemid 44750737)
17. Vultur A, Cao J, Arulanandam R, et al. Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene 2004;2315:2600-2616 (Pubitemid 38586314)
18. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004;10(1):48-54 • First evidence of a role of Stat3 in regulation of immune responses in tumor cells. (Pubitemid 38524698)
19. Bhattacharya S, Ray RM, Johnson LR. STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J 2005;392(Pt 2):335-344
20. Turkson J, Kim JS, Zhang S, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 2004;3(3):261-269 •• First evidence for peptidomimetics as Stat3 inhibitors by disruption of Stat3 dimerization. (Pubitemid 39193701)
21. Ren Z, Cabell LA, Schaefer TS, McMurray JS. Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg Med Chem Lett 2003;13(4):633-636 (Pubitemid 36298456)
22. Coleman DRT, Ren Z, Mandal PK, et al. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. J Med Chem 2005;48(21):6661-6670 (Pubitemid 41504722)
23. Buerger C, Nagel-Wolfrum K, Kunz C, et al. Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J Biol Chem 2003;278(39):37610-37621 (Pubitemid 37175284)
24. Nagel-Wolfrum K, Buerger C, Wittig I, et al. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol Cancer Res 2004;2(3):170-182 (Pubitemid 39030307)
25. Song H, Wang R, Wang S, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005;102(13):4700-4705 • First example of the nonpeptidic chemical inhibitors of Stat3 via targeting its SH2 domain. (Pubitemid 40471517)
26. Chen CL, Loy A, Cen L, et al. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 2007;7:111 (Pubitemid 47381858)
27. Bhasin D, Cisek K, Pandharkar T, et al. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem Lett 2008;18(1):391-395
28. Schust J, Sperl B, Hollis A, et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006;13(11):1235-1242 (Pubitemid 44750735)
29. Hao W, Hu Y, Niu C, et al. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening. Bioorg Med Chem Lett 2008;18(18):4988-4992
30. Turkson J, Zhang S, Mora LB, et al. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 2005;280(38):32979-32988 (Pubitemid 41368347)
31. Turkson J, Zhang S, Palmer J, et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 2004;3(12):1533-1542 (Pubitemid 40136708)
32. Weidler M, Rether J, Anke T, Erkel G. Inhibition of interleukin-6 signaling by galiellalactone. FEBS Lett 2000;484(1):1-6 (Pubitemid 30803730)
33. Hellsten R, Johansson M, Dahlman A, et al. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. Prostate 2008;68(3):269-280 (Pubitemid 351273056)
34. Borghouts C, Kunz C, Delis N, Groner B. Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition. Mol Cancer Res 2008;6(2):267-281 (Pubitemid 351342415)
35. Gao L, Zhang L, Hu J, et al. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 2005;11(17):6333-6341 (Pubitemid 41262965)
36. Konnikova L, Kotecki M, Kruger MM, Cochran BH. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 2003;3:23 (Pubitemid 38851326)
37. Ling X, Arlinghaus RB. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 2005;65(7):2532-2536 (Pubitemid 40490046)
38. Son G, Iimuro Y, Seki E, et al. Selective inactivation of NF-kappaB in the liver using NF-kappaB decoy suppresses CCl4-induced liver injury and fibrosis. Am J Physiol Gastrointest Liver Physiol 2007;293(3):G631-9 (Pubitemid 47435392)
39. Bezzerri V, Borgatti M, Nicolis E, et al. Transcription factor oligodeoxynucleotides to NF-kappaB inhibit transcription of IL-8 in bronchial cells. Am J Respir Cell Mol Biol 2008;39(1):86-96 (Pubitemid 351883962)
40. Moriyama I, Ishihara S, Rumi MA, et al. Decoy oligodeoxynucleotide targeting activator protein-1 (AP-1) attenuates intestinal infl ammation in murine experimental colitis. Lab Invest 2008;88(6):652-663 (Pubitemid 351733283)
41. Tomita N, Ogihara T, Morishita R. Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their design. Curr Drug Targets 2003;4(8):603-608 (Pubitemid 37236375)
42. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003;100(7):4138-4143 (Pubitemid 36418170)
43. Barton BE, Murphy TF, Shu P, et al. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol Cancer Ther 2004;3(10):1183-1191 (Pubitemid 39440162)
44. Aggarwal BB, Sethi G, Ahn KS, et al. Targeting signal-transducer-and- activatorof- transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann NY Acad Sci 2006;1091:151-169 (Pubitemid 47092233)
45. Sun X, Zhang J, Wang L, Tian Z. Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 2008;262(2):201-213
46. Zhang X, Zhang J, Wang L, et al. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 2007;7:149 (Pubitemid 47470219)
47. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005;24(6):970-979
48. Morishita R, Aoki M, Ogihara T. Does gene therapy become pharmacotherapy? Exp Physiol 2005;90(3):307-313
49. Jing N, Li Y, Xu X, et al. Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. DNA Cell Biol 2003;22(11):685-696 • First evidence of G-rich oligonucleotides as Stat3 inhibitors. (Pubitemid 37468167)
50. Zhu Q, Jing N. Computational study on mechanism of G-quartet oligonucleotide T40214 selectively targeting Stat3. J Comput Aided Mol Des 2007;21(10-11):641-648 • First proof-of-principle for G-rich oligonucleotides as Stat3 inhibitors by interfering Stat3 dimerization. (Pubitemid 50005008)
51. Jing N, Li Y, Xiong W, et al. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res 2004;64(18):6603-6609 (Pubitemid 39297920)
52. Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998;394(6689):145-151 (Pubitemid 28325960)
53. Timofeeva OA, Gaponenko V, Lockett SJ, et al. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem Biol 2007;2 (12):799-809 •• First proof-of-concept for inhibition of Stat3 function via targeting its N-terminal domain. (Pubitemid 351166055)
54. Blaskovich MA, Sun J, Cantor A, et al. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003;63 (6):1270-1279 (Pubitemid 36348705)
55. van Kester MS, Out-Luiting JJ, von dem Borne PA, et al. Cucurbitacin I inhibits Stat3 and induces apoptosis in Sezary cells. J Invest Dermatol 2008;128(7):1691-1695 (Pubitemid 351847375)
56. Shi X, Franko B, Frantz C, et al. JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. Br J Haematol 2006;135(1):26-32 (Pubitemid 44337660)
57. Su Y, Li G, Zhang X, et al. JSI-124 Inhibits Glioblastoma Multiforme Cell Proliferation through G2/M Cell Cycle Arrest and Apoptosis Augment. Cancer Biol Ther 2008;7(8):1243-1249
58. Nefedova Y, Nagaraj S, Rosenbauer A, et al. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic- selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005;65(20):9525-9535 (Pubitemid 41508023)
59. Sun J, Blaskovich MA, Jove R, et al. a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005;24(20):3236-3245 (Pubitemid 40695105)
60. Liu T, Zhang M, Zhang H, et al. Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur J Pharmacol 2008;587(1-3):78-84
61. Tannin-Spitz T, Grossman S, Dovrat S, et al. Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem Pharmacol 2007;73(1):56-67 (Pubitemid 44853933)
62. Levitzki A. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J 1992;6(14):3275-3282
63. Ferrajoli A, Faderl S, Van Q, et al. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 2007;67(23):11291-11299 (Pubitemid 350248555)
64. Iwamaru A, Szymanski S, Iwado E, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007;26(17):2435-2444 (Pubitemid 46597261)
65. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007;21(8):1658-1668 (Pubitemid 47086756)
66. Kotha A, Sekharam M, Cilenti L, et al. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 2006;5(3):621-629
67. Nam S, Buettner R, Turkson J, et al. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 2005;102(17):5998-6003 (Pubitemid 40594244)
68. Lee MJ, Kim MY, Mo JS, et al. Indirubin-3′-monoxime, a derivative of a Chinese anti-leukemia medicine, inhibits Notch1 signaling. Cancer Lett 2008;265(2):215-225
69. Natarajan C, Bright JJ. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 2002;168(12):6506-6513 (Pubitemid 34620077)
70. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003;171(7):3863-3871 (Pubitemid 37254592)
71. Kagialis-Girard S, Mialou V, Chebel A, et al. Inhibition of normal lymphocyte proliferation by Indirubin-3′-monoxime: a multifactorial process. Leuk Lymphoma 2007;48(3):605-615 (Pubitemid 46487771)
72. Gonzales AM, Orlando RA. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr Metab (Lond) 2008;5:17 (Pubitemid 351904902)
73. Mackenzie GG, Queisser N, Wolfson ML, et al. Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin's lymphoma cells. Int J Cancer 2008;123(1):56-65 (Pubitemid 351705192)
74. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995;269(5220):81-83
75. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19(21):2474-2488 (Pubitemid 30339203)
76. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008;18(2):254-267 (Pubitemid 351206162)
77. Fletcher S, Turkson J, Gunning PT. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 2008;3(8):1159-1168
78. Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003;30 (5 Suppl 16):133-142 (Pubitemid 37433404)
79. Mohammad RM, Goustin AS, Aboukameel A, et al. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 2007;13(7):2226-2235 (Pubitemid 46649892)
80. Mohammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 2005;4(1):13-21 .